Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a cornerstone in managing type 2 diabetes (T2D) and obesity, demonstrating benefits that extend far beyond glycaemic control. Initially developed for metabolic regulation, several large-scale cardiovascular outcome trials (CVOTs) have redefined their role by proving significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

Pivotal trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) consistently demonstrated class-wide superiority or non-inferiority in reducing MACE. Notably, the recent SELECT trial expanded these benefits to non-diabetic, obese patients with established cardiovascular disease, marking a paradigm shift toward broad cardiometabolic protection. Emerging evidence from the STEP-HFpEF trial also highlights semaglutide’s efficacy in improving symptoms and exercise capacity in heart failure patients with preserved ejection fraction.

The cardioprotective mechanisms of GLP-1 RAs are multifaceted, involving pleiotropic effects such as anti-inflammatory action (reducing CRP and TNF-α), improved endothelial function via nitric oxide production, blood pressure reduction, and direct anti-atherogenic properties. Furthermore, trials like FLOW have recently confirmed substantial Reno protective benefits, showing a 24% reduction in kidney failure events.

In conclusion, GLP-1 RAs provide robust cardiovascular and renal protection across diverse populations. Their ability to mitigate atherosclerotic risk and improve mortality makes them essential in modern treatment algorithms for high-risk patients. Future research on dual/triple agonists like tirzepatide continues to investigate even greater potential for cardiovascular risk reduction.

TBA..